IPO Theranexus

Listing of Theranexus on Euronext Growth

Franck Mouthon and Mathieu Charvériat, founders of Theranexus, open the trading day in Paris

Theranexus is an innovative biopharmaceutical company specializing in the development of therapeutic products for the treatment of central nervous system diseases. Theranexus now has one product (THN102; a drug candidate combining a modulator of neuronal activity with a glial connexin modulator for the treatment of narcolepsy, a rare neurological disease) in Phase II clinical trial.